Latest News

Sensidose AB (the "Company") has entered into a service agreement with Desitin Arzneimittel GmbH ("Desitin") for the sales and marketing of Flexilev (under the trade name Suades) in Germany. Sensidose and Desitin will share the revenue from the sales. The launch is...

Sensidose receives SEK 1.22 million in grants from Vinnova for industrial research within the call "Innovation projects in companies". The funding aims to support the company's development of measuring physiological reactions to pain to enable improved pain relief and...

Sensidose participated in the Swedish-American Life Science Summit (SALSS) between the 22nd to 24th of August 2018 in Stockholm, Sweden. The summit is a by-invitation-only conference bringing together some of the most renowned Life Science executives, scientists,...

The Annual General Meeting was held on May 29 at the company's premises in Sollentuna. The chairman of the meeting was elected lawyer Mikael Smedeby from Lindahl's law firm. At the annual meeting, Gunnar Säll, after 5 years as the chairman resigned. Proposed new...

Sensidose has strengthened its market with the employment of Pontus Salomonsson, who takes the role of sales and marketing manager . Pontus comes departed from Grünenthal where he was the head of Parkinson in the Nordic region. Prior to that, he has worked at Lundbeck...

Sensidose participated in BIO-Europe® 2016 - 22nd Annual International Partnering Conference Sensidose has participated in the BIO-Europe® 2016, the 22nd Annual International Partnering Conference that was held November 7-9, 2016 in Cologne, Germany. At the...